Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial

February 14, 2024

Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (https://www.nature.com/articles/s41591-024-02805-1), demonstrating the unique potential of our lead first-in-class MYC inhibitor, OMO-103, to treat multiple oncological indications. Peptomyc takes pride in pioneering the blockade of a most-wanted target in cancer, and we believe this encouraging data, along with our preclinical findings, underscore the importance of MYC inhibition in the treatment of cancer.


Read more